$ARAY

Accuray Incorporated (NASDAQ: ARAY) said it appointed Todd Brown to lead a newly created Enterprise Performance Optimization organization and named Sofiane Laoussadi as Senior VP, Global Services & Solutions. The company links the hires to its Transformation Phase II plan to improve execution, lower costs, and boost customer value. Accuray said services generated 57% of fiscal 2026 net revenues.

Samsung Electronics’ Medical Device Business Division and Samsung Medison said they are expanding partnerships beyond diagnostic imaging. They signed a non-binding LOI with U.S. radiosurgery specialist Accuray to explore integrating Samsung’s mobile CT (BodyTom) with Accuray’s CyberKnife for volumetric imaging-based precision radiation therapy. Samsung also referenced an expanded collaboration with HistoSonics.

Accuray Inc. (NASDAQ: ARAY) said it reached definitive agreements with its primary lender and largest shareholder, TCW Asset Management, to delever $40 million via convertible preferred stock, add $15 million equity investment, and potentially access a delayed draw term loan up to $5 million. The plan includes covenant waivers through Dec. 31, 2027, board changes, and a reverse stock split. Accuray also outlined non-binding LOIs with Samsung HME America and RaySearch, plus expanded work with Tat

ACCURAY INC (ARAY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 4 ex_995040.htm EXHIBIT 10.2 ex_995040.htm Exhibit 10.2 LIMITED WAIVER AND AMENDMENT NO. 3 TO FINANCING AGREEMENT This LIMITED WAIVER AND AMENDMENT NO. 3 TO FINANCING AGREEMENT (this “ Amendment ”) dated as of July 29, 2026, is made by and among Accuray Incorporated, a De

Accuray Incorporated (NASDAQ:ARAY) insiders lost US$95k on their investments after a 17% stock drop, despite purchasing US$216.4k worth of stock at an average of US$0.68 over the past year. Director Steven Mayer recently bought US$135k worth of shares, indicating continued confidence, though overall insider ownership is relatively low at 4.8%. The company's recent losses warrant caution for potential investors.

Accuray Incorporated has announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will lead the company's global commercial organization, focusing on transformation, strengthening execution, and enhancing commercial performance. His extensive experience in medical technology, including a commercial turnaround at Johnson & Johnson MedTech, is expected to drive Accuray's long-term value creation and growth in systems and services sales.

This page provides a comprehensive resource for Accuray Incorporated (ARAY) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms (Form 4). It highlights how these documents provide insights into the company's financial performance, governance, and key corporate events, with AI-powered summaries to help users quickly grasp the significance of each filing. Recent filings cover topics such as director ownership, quarterly financial results, executive compensation, and equity grants.

ACCURAY INC (ARAY) has filed an EFFECT form with the SEC, indicating the effectiveness of its S-3 Shelf Registration Statement as of February 27, 2026, at 9:00 A.M. This filing is deemed neutral in both impact and sentiment by Rhea-AI. The company's recent news includes reporting Q2 2026 financial results and announcing a strategic transformation plan.

Institutional investors, holding 59% of Accuray Incorporated (NASDAQ:ARAY), may be encouraged by a recent 11% share price increase after a year-long 59% decline. BlackRock, Inc. is the largest shareholder with 7.7%, and insiders collectively own US$4.8 million worth of stock. The general public maintains a 36% stake in the company.

MADISON, Wis., Sept. 30, 2025 /PRNewswire/ -- Accuray Incorporated ( NASDAQ:ARAY ) and the University of Wisconsin School of Medicine and Public Health ( UW SMPH ) announced today the signing of a memorandum of understanding ( MOU ) to advance online adaptive radiotherapy ( OART ) on the Accuray ...